Abstract Details

Title Impact on Healthcare Resource Utilization in Early Initiators of Ravulizumab or Efgartigimod for Treatment of Generalized Myasthenia Gravis in the U.S.A.

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-017

Objective This study aims to present real-world evidence demonstrating the impact of both ravulizumab and efgartigimod on gMG-related healthcare resource utilization in patients initiating treatment within 2 years of diagnosis.

Background

Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular disorder characterized by fatigable muscle weakness. Suboptimally treated gMG can result in clinical deterioration, hospitalizations, and increased healthcare resource utilization. Ravulizumab, a complement C5 inhibitor, and efgartigimod, an FCRn inhibitor, are US FDA-approved therapies for anti-acetylcholine receptor antibody positive gMG.

Design/Methods Patients initiating ravulizumab or efgartigimod within 2 years of diagnosis were identified in Atlas (Definitive Healthcare), a hybrid open/closed US claims database set between 01/2017 to 12/2024. Patients had ≥1 year of continuous follow-up before and after initiation. The study compared hospitalizations and other healthcare resource utilization before and after initiation of ravulizumab or efgartigimod.

Results There were 114 ravulizumab patients and 639 efgartigimod patients who met the inclusion criteria. Initiators of ravulizumab within 2 years of diagnosis experienced an 81% (IRR=0.19; 95% CI: 0.12, 0.30; p<0.001) reduction in all-cause hospitalization compared to a 32% reduction (IRR=0.68; 95% CI: 0.53, 0.87; p=0.002) in early initiators of efgartigimod (p_comparison<0.001). Similar trends observed for other healthcare resource endpoints will additionally be reported.

Conclusions Patients who initiated ravulizumab or efgartigimod within 2 years of diagnosis had significant reductions in healthcare resource utilization. However, those who started on ravulizumab had statistically significantly greater reduction. Timely initiation of potentially disease-modifying targeted treatments, such as C5 inhibitor therapy, may have implications for reducing healthcare resource utilization in patients with gMG.

Authors/Disclosures
Riley J. Snook, MD (Indiana University Health) PRESENTER	Dr. Snook has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Snook has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Snook has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen.
Michael Blackowicz, PhD (Alexion)	Dr. Blackowicz has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Dr. Blackowicz has stock in Alexion Pharmaceuticals.
Emma Weiskopf, MD (Alexion Pharmaceuticals)	Dr. Weiskopf has received personal compensation for serving as an employee of Alexion AstraZeneca Rare Disease. Dr. Weiskopf has stock in Alexion Astrazeneca Rare Disease.
Dan Fogarty	Mr. Fogarty has nothing to disclose.
Neha Arora	Ms. Arora has nothing to disclose.
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group)	Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��